FDA probes prostate meds for diabetes, heart risks

The FDA announced that it's reviewing the safety of a class of prostate cancer drugs, following up on data that suggest an increased risk of diabetes and certain heart problems.The agency is sifting data from published studies of drugs that fight gonadotropin-releasing hormone, used to treat men with prostate cancer. At issue: whether the GnRH agonists carry an increased risk of diabetes or heart trouble compared with other prostate meds. The products involved in the probe are Abbott Laboratories' Lupron, AstraZeneca's Zoladex, Watson Pharmaceuticals' Trelstar, Endo Pharmaceutical Holdings' Vantas, Sanofi-Aventis' Eligard and Pfizer's Synarel..........................& more.

No comments:

Post a Comment